Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 4
1978 3
1979 1
1980 1
1981 2
1982 3
1983 4
1984 2
1985 4
1989 2
1990 2
1991 2
1993 2
1994 2
1996 4
1997 3
1998 2
1999 3
2000 4
2001 3
2002 8
2003 5
2004 7
2005 4
2006 9
2007 16
2008 9
2009 17
2010 12
2011 18
2012 21
2013 14
2014 16
2015 18
2016 18
2017 10
2018 22
2019 28
2020 37
2021 47
2022 40
2023 29
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

420 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, Damasceno A, Avezum A, Dans AML, Gitura B, Hu D, Kamanzi ER, Maklady F, Fana G, Gonzalez-Hermosillo JA, Musuku J, Kazmi K, Zühlke L, Gondwe L, Ma C, Paniagua M, Ogah OS, Molefe-Baikai OJ, Lwabi P, Chillo P, Sharma SK, Cabral TTJ, Tarhuni WM, Benz A, van Eikels M, Krol A, Pattath D, Balasubramanian K, Rangarajan S, Ramasundarahettige C, Mayosi B, Yusuf S; INVICTUS Investigators. Connolly SJ, et al. N Engl J Med. 2022 Sep 15;387(11):978-988. doi: 10.1056/NEJMoa2209051. Epub 2022 Aug 28. N Engl J Med. 2022. PMID: 36036525 Clinical Trial.
Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Giugliano RP, et al. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251359 Free article. Clinical Trial.
Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness.
Töpf A, Johnson K, Bates A, Phillips L, Chao KR, England EM, Laricchia KM, Mullen T, Valkanas E, Xu L, Bertoli M, Blain A, Casasús AB, Duff J, Mroczek M, Specht S, Lek M, Ensini M, MacArthur DG; MYO-SEQ consortium; Straub V. Töpf A, et al. Genet Med. 2020 Sep;22(9):1478-1488. doi: 10.1038/s41436-020-0840-3. Epub 2020 Jun 11. Genet Med. 2020. PMID: 32528171 Free PMC article.
n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease.
Dry Eye Assessment and Management Study Research Group; Asbell PA, Maguire MG, Pistilli M, Ying GS, Szczotka-Flynn LB, Hardten DR, Lin MC, Shtein RM. Dry Eye Assessment and Management Study Research Group, et al. N Engl J Med. 2018 May 3;378(18):1681-1690. doi: 10.1056/NEJMoa1709691. Epub 2018 Apr 13. N Engl J Med. 2018. PMID: 29652551 Free PMC article. Clinical Trial.
Rebalancing Immune Homeostasis to Treat Autoimmune Diseases.
Horwitz DA, Fahmy TM, Piccirillo CA, La Cava A. Horwitz DA, et al. Trends Immunol. 2019 Oct;40(10):888-908. doi: 10.1016/j.it.2019.08.003. Epub 2019 Oct 7. Trends Immunol. 2019. PMID: 31601519 Free PMC article. Review.
Multiplexed SOI BioFETs.
Vacic A, Criscione JM, Stern E, Rajan NK, Fahmy T, Reed MA. Vacic A, et al. Biosens Bioelectron. 2011 Oct 15;28(1):239-42. doi: 10.1016/j.bios.2011.07.025. Epub 2011 Jul 23. Biosens Bioelectron. 2011. PMID: 21820303 Free PMC article.
Liposome Photosensitizer Formulations for Effective Cancer Photodynamic Therapy.
Fahmy SA, Azzazy HME, Schaefer J. Fahmy SA, et al. Pharmaceutics. 2021 Aug 27;13(9):1345. doi: 10.3390/pharmaceutics13091345. Pharmaceutics. 2021. PMID: 34575424 Free PMC article. Review.
This generates highly reactive oxygen species (such as (1)O(2), H(2)O(2), O(2), .OH), which kill cancer cells by necrosis or apoptosis. ...
This generates highly reactive oxygen species (such as (1)O(2), H(2)O(2), O(2), .OH), which kill cancer cells by necrosis or apoptosi …
420 results